• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    TriSalus Life Sciences, Inc. - Common Stock (NQ:TLSI)

    4.560 -0.210 (-4.40%)
    Streaming Delayed Price Updated: 2:59 PM EST, Mar 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about TriSalus Life Sciences, Inc. - Common Stock

    < Previous 1 2 Next >
    News headline image
    TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Proposes Public Offering
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences to Participate in Upcoming Investor Conferences
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Announces Key Appointments to Board of Directors
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
    From TriSalus Life Sciences
    Via Business Wire
    News headline image
    TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
    From TriSalus Life Sciences
    Via Business Wire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.